Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IQWiG’s First Cost-Effectiveness Review Could Take Drug HTA To New Frontiers

This article was originally published in The Pink Sheet Daily

Executive Summary

Germany’s reimbursement watchdog IQWiG’s first cost-effectiveness analysis uses four antidepressants as test case and finds they are overpriced.

You may also be interested in...



German Pricing Mechanism Adds Weak Economies, Could Spell Trouble For EU Industry

The decision by the German pharmaceutical arbitration committee to include countries such as Greece in a final pricing mechanism will cut German prices and may have a Europe-wide effect.

Sweden Leads In Linking Regulatory And Reimbursement Scientific Advice

Sweden has been offering joint scientific advice to drug developers via a collaborative project between the country's reimbursement authority (TLV) and the Medical Products Agency (MPA).

MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins

In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.

Topics

Related Companies

UsernamePublicRestriction

Register

PS051363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel